At the recent EAACI meeting, researchers presented preclinical data for the inflammasome inhibitor OLT-1177 (dapansutrile), which is being evaluated by Olatec Therapeutics LLC for the treatment of inflammatory diseases.
Elgen Therapeutics Inc. has described histone-lysine N-methyltransferase 2A (KMT2A, MLL1) inhibitors reported to be useful for the treatment of cancer.
Chengdu Baiyu Pharmaceutical Co Ltd. has divulged poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors with improved blood-brain barrier penetration ability and reported to be useful for the treatment of cancer.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to a Bruton tyrosine kinase (BTK) targeting moiety via linker and thus acting as BTK degradation inducers.
Chemokine (C-C motif) receptor 8 (CCR8), a member of the β chemokine receptor family, contributes to the recruitment and immunosuppressive function of regulatory T (Treg) cells within the tumor microenvironment.
Tetra Pharm Technologies Aps has announced promising results from preclinical testing of its pain-relieving drug, TPT-0301, which targets the endocannabinoid system.
CSPC Pharmaceutical Group Ltd. has received clinical trial clearance by China’s National Medical Products Administration (NMPA) for SYH-2051 for solid tumors.
Lantern Pharma Inc. has received IND clearance from the FDA for LP-184, which is being developed for advanced solid tumors and central nervous system (CNS) cancers.
RSS
